Rivastigmine (tartrate)

Names

[ Name ]:
Rivastigmine (tartrate)

[Synonym ]:
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (1:1)
acide (2R,3R)-2,3-dihydroxybutanedioïque - éthyl(méthyl)carbamate de 3-[(1S)-1-(diméthylamino)éthyl]phényle (1:1)
RivastigMine L-Tartrate
Rivastigmine Tartrate Salt
N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate
Rivastigmine
(2R,3R)-2,3-Dihydroxysuccinic acid - 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate (1:1)
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R,3R)-2,3-dihydroxysuccinate
Rivastigmine Tartrate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate 2,3-dihydroxybutanedioate (salt)
(2R,3R)-2,3-Dihydroxybutandisäure--3-[(1S)-1-(dimethylamino)ethyl]phenyl-ethyl(methyl)carbamat(1:1)
3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate
Rivastigmine hydrogen tartrate
Rivastigmine (tartrate)

Biological Activity

[Description]:

Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

[Related Catalog]:

Signaling Pathways >> Neuronal Signaling >> AChE

Research Areas >> Neurological Disease

[References]

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
316.2ºC at 760 mmHg

[ Melting Point ]:
123-1250C

[ Molecular Formula ]:
C₁₈H₂₈N₂O₈

[ Molecular Weight ]:
400.423

[ Flash Point ]:
145ºC

[ Exact Mass ]:
400.184570

[ PSA ]:
147.84000

[ LogP ]:
0.63710

[ Vapour Pressure ]:
0.000416mmHg at 25°C

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Codes ]:
Xi

[ Safety Phrases ]:
36

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2942000000

Customs

[ HS Code ]: 2942000000

Articles

[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].

Minerva Med. 105(2) , 167-74, (2014)

Vascular dementia (VaD) is defined as a loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. The ...

Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.

Int. J. Geriatr. Psychiatry 28(12) , 1312-7, (2013)

A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim...

Rivastigmine for vascular cognitive impairment.

Cochrane Database Syst. Rev. 5 , CD004744, (2013)

Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common...